Keystone Financial Planning Inc. raised its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 3.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 27,976 shares of the medical research company’s stock after acquiring an additional 1,034 shares during the period. Amgen comprises approximately 2.8% of Keystone Financial Planning Inc.’s portfolio, making the stock its 20th biggest holding. Keystone Financial Planning Inc.’s holdings in Amgen were worth $5,164,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of AMGN. HC Financial Advisors Inc. bought a new stake in Amgen in the fourth quarter valued at about $1,924,000. QS Investors LLC increased its stake in Amgen by 5.8% in the fourth quarter. QS Investors LLC now owns 124,774 shares of the medical research company’s stock valued at $21,698,000 after acquiring an additional 6,863 shares during the period. Guggenheim Capital LLC increased its stake in Amgen by 1.5% in the fourth quarter. Guggenheim Capital LLC now owns 734,266 shares of the medical research company’s stock valued at $127,690,000 after acquiring an additional 10,980 shares during the period. Kendall Capital Management bought a new stake in Amgen in the fourth quarter valued at about $1,341,000. Finally, Teachers Insurance & Annuity Association of America increased its stake in Amgen by 4.7% in the fourth quarter. Teachers Insurance & Annuity Association of America now owns 51,876 shares of the medical research company’s stock valued at $9,022,000 after acquiring an additional 2,332 shares during the period. Institutional investors and hedge funds own 80.04% of the company’s stock.

In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction dated Monday, July 16th. The shares were sold at an average price of $195.71, for a total transaction of $298,457.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.27% of the stock is currently owned by corporate insiders.

AMGN has been the topic of a number of analyst reports. TheStreet raised shares of Amgen from a “c+” rating to a “b-” rating in a research note on Friday, May 25th. Morgan Stanley upped their target price on shares of Amgen from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Friday, July 13th. Mizuho set a $200.00 target price on shares of Amgen and gave the company a “buy” rating in a research note on Tuesday, April 24th. Cowen reissued a “buy” rating and issued a $204.00 target price on shares of Amgen in a research note on Tuesday, April 24th. Finally, Zacks Investment Research raised shares of Amgen from a “hold” rating to a “buy” rating and set a $207.00 target price on the stock in a research note on Tuesday, June 26th. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating and twelve have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $202.76.

Shares of Amgen stock opened at $197.42 on Monday. The company has a current ratio of 3.39, a quick ratio of 3.12 and a debt-to-equity ratio of 2.03. The stock has a market cap of $125.84 billion, a price-to-earnings ratio of 15.69, a PEG ratio of 1.90 and a beta of 1.36. Amgen, Inc. has a 1-year low of $163.31 and a 1-year high of $201.23.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Thursday, July 26th. The medical research company reported $3.83 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.52 by $0.31. The firm had revenue of $6.06 billion for the quarter, compared to analysts’ expectations of $5.73 billion. Amgen had a net margin of 10.19% and a return on equity of 43.18%. The company’s quarterly revenue was up 4.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.27 earnings per share. equities analysts anticipate that Amgen, Inc. will post 13.95 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 7th. Shareholders of record on Friday, August 17th will be paid a dividend of $1.32 per share. The ex-dividend date of this dividend is Thursday, August 16th. This represents a $5.28 annualized dividend and a yield of 2.67%. Amgen’s dividend payout ratio is 41.97%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Further Reading: How to Use the New Google Finance Tool

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.